SAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that the company has completed enrollment of its latest Phase 2 clinical study of RTX for treating moderate-to-severe osteoarthritis of the knee pain (OAK).
CANTON, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that third quarter of fiscal year 2022 financial results will be reported after the market closes on Wednesday, November 9th.
Original post:
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2022 Financial Results on November 9, 2022
CUMBERLAND, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and commercialize interventions to address chronic and acute pulmonary (lung) inflammation-based diseases, is pleased to announce that is has secured a $3 million Seed II round of funding.
Visit link:
RS BioTherapeutics Secures $3 Million Seed II Round of Funding
Parallel processing using TCXpress™ and iTCXpress™ platforms significantly increases throughput, reduces the cost and shortens the timing of identifying novel TCRs Parallel processing using TCXpress™ and iTCXpress™ platforms significantly increases throughput, reduces the cost and shortens the timing of identifying novel TCRs
Continued here:
BlueSphere Bio Presents Data Demonstrating Efficiency of Parallel TCR Capture and Bioinformatics Platforms at 7th Annual CAR-TCR Summit
- Order for Approximately $10 Million Funded by the European Commission –
See original here:
SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat)
Company announcementOrphazyme A/SNo. 36/2022 www.orphazyme.comCompany Registration No. 32266355
See original here:
Orphazyme reports financial results in Interim Report First Half 2022
Guerbet obtains one million euros of public funding from Bpifrance (France 2030 investment plan) for a project developing artificial intelligence for the early detection of pancreatic cancer
Originally posted here:
Guerbet obtains one million euros of public funding from Bpifrance (France 2030 investment plan) for a project developing artificial intelligence for...
Mupadolimab clinical trial in China will be conducted by Angel Pharmaceuticals Mupadolimab clinical trial in China will be conducted by Angel Pharmaceuticals
Go here to see the original:
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China
- $238 Million in Upfront Payment Received at Closing with Additional $136.5 Million in Potential Milestone Payments Plus Royalties -
Read more:
Chimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions
AUSTIN, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that Lumos Pharma management will participate in a panel discussion and host one-on-one meetings at the Cantor Neurology & Psychiatry Conference in October.
Read more here:
Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference